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Abstract
Pigment epithelium–derived factor (PEDF) is a potent inhibitor of angiogenesis but whether it has additional ef-
fects on the tumor microenvironment is largely unexplored. We show that overexpression of PEDF in orthotopic
MatLyLu rat prostate tumors increased tumor macrophage recruitment. The fraction of macrophages expressing
inducible nitric oxide synthase, a marker of cytotoxic M1 macrophages, was increased, suggesting that PEDF
could enhance antitumor immunity. In addition, PEDF overexpression reduced vascular growth both in the tumor
and in the surrounding normal tissue, slowed tumor growth, and decreased lymph node metastasis. Contrary,
extratumoral lymphangiogenesis was increased. PEDF expression is, for reasons unknown, often decreased or
lost during prostate tumor progression. When AT-1 rat prostate tumor cells, expressing high levels of PEDF mes-
senger RNA (mRNA) and protein, were injected into the prostate, PEDF is markedly downregulated, suggesting
that factors in the microenvironment suppressed its expression. One such factor could be macrophage-derived
tumor necrosis factor α (TNFα). A fraction of the accumulating macrophages expressed TNFα, and TNFα treat-
ment downregulated the expression of PEDF protein and mRNA in prostate AT-1 tumor cells in vitro and in the
rat ventral prostate in vivo. PEDF apparently has multiple effects in prostate tumors: it suppresses angiogenesis
and metastasis, but it also causes macrophage accumulation. Accumulating macrophages may inhibit tumor
growth, but they may also suppress PEDF and enhance lymph angiogenesis and, in this way, eventually enhance
tumor growth.
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Introduction
Prostate tumors contain, in addition to tumor epithelial cells, many
different cancer-associated stromal cells, including cancer-associated fi-
broblasts, infiltrating immune cells and blood vessels. The cancer cells
alter the stromal cells, activating them such that this microenvi-
ronment becomes largely tumor promoting [1]. Macrophages are the
most abundant immune cells present in the tumor microenvironment
[2]. Tumor-associated macrophages (TAMs) may have both tumor-
stimulatory and/or -inhibitory properties, probably because they can,
by mechanisms largely unknown, differentiate into either cytotoxic
(M1) or tumor growth-promoting (M2) states. Classically, proin-
flammatory (M1) macrophages express inducible nitric oxide synthase
(iNOS) in contrast to immunosuppressive (M2) macrophages [3].
Abbreviations: CCL2/MCP-1, monocyte chemoattractant protein 1; FGF2, fibroblast
growth factor 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; iNOS, induc-
ible nitric oxide synthase; PEDF, pigment epithelium–derived factor; PlGF, placental
growth factor; TAM, tumor-associated macrophage; TLR4, Toll-like receptor 4; TNFα,
tumor necrosis factor α; VEGF, vascular endothelial growth factor
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TAMs generally exhibit an M2 phenotype known to promote angio-
genesis, tumor growth, and metastasis [3,4].
In prostate cancer, the significance of macrophage infiltration is
unclear. In one study, the presence of macrophages was associated
with angiogenesis and poor outcome [5], but another study reported
no association [6]. A study in mice showed that inhibition of the
macrophage chemoattractant, monocyte chemoattractant protein 1
(MCP-1; also called CCL2), in a prostate xenograft model reduced
macrophage infiltration, angiogenesis, and tumor growth [7]. We have
previously shown that an overall reduction of monocyte/macrophage
recruitment to orthotopic rat prostate tumors represses tumor growth
and angiogenesis both in the tumor and in the surrounding non-
malignant tissue [8]. However, none of these studies distinguished
between M1 and M2 TAM subtypes.
Pigment epithelium–derived factor (PEDF), a 50-kDa secreted
glycoprotein with multifunctional properties, has also been impli-
cated in both proinflammatory and anti-inflammatory processes in
neuronal tissues and in the eye [9–13]; however, its role in tumor
inflammation is unknown. PEDF also functions in neuronal cell sur-
vival and differentiation [14] and has potent antiangiogenic activity
[15]. Owing to its antiangiogenic properties, the potential antitumor
activity of PEDF has been investigated. To date, a number of studies
have demonstrated that PEDF represses tumor growth and sup-
presses metastasis in several types of cancers [16–22]. The antitumor
effects of PEDF include both indirect actions through inhibition of
angiogenesis and direct inhibition of tumor cell migration, induction
of apoptosis, and differentiation [23–25].
In prostate cancer, treatment of subcutaneous prostate xenografts
with recombinant PEDF protein inhibited angiogenesis and increased
tumor necrosis [26]. Treatments with different PEDF epitopes have
also shown to inhibit growth of experimental prostate tumors either
through antiangiogenic effects or by inducing neuroendocrine differ-
entiation [27]. We have earlier shown that decreased PEDF levels
are associated with a higher vascular density and a metastatic pheno-
type in both human and rat prostate tumors [28]. An inverse correla-
tion among PEDF levels, grade, and metastatic potential has also been
seen for several other tumors, indicating that PEDF expression is de-
creased during tumor progression [29–34].
The underlying mechanisms for decreased PEDF expression in tu-
mors are unknown but could be due to genetic or epigenetic changes.
Regulatory signals from the microenvironment may also influence
PEDF expression. Hypoxia and androgens have, for instance, been
shown to downregulate PEDF in prostate tumors [26].
In this study, MatLyLu rat prostate tumor cells transfected to over-
express human PEDF were examined for tumor growth, angiogenesis,
lymphangiogenesis, metastasis, and tumor macrophage infiltration.
Furthermore, we examined prostate environmental regulation of PEDF
in rat prostate tumors.
Consistent with previous studies, the current study shows that
PEDF overexpression suppresses orthotopic rat prostate tumor growth,
angiogenesis, and metastasis, although it increased extratumoral lymph-
angiogenesis. We also show that endogenous PEDF is downregulated
by the prostate microenvironment. We demonstrate that this down-
regulation is likely due in part to macrophage-derived tumor necrosis
factor α (TNFα) because TNFα down-regulated PEDF expression in
prostate tumor cells in vitro and in the ventral prostate in vivo. In ad-
dition, we show that PEDF increased tumor macrophage infiltration
and increased the fraction of iNOS-positive TAMs in the tumors, sug-
gesting an increase in tumoricidal M1 macrophage activity.
Materials and Methods
Cell Culture
Tumor cell lines (ATCC, LGCStandards, Borås, Sweden)were grown
in RPMI 1640 with 10% fetal calf serum, 0.2%Na-Bic, 50 μg/ml gen-
tamicin, and 250 nM dexamethasone in 37°C and 5% CO2. Human
umbilical vein endothelial cells (Cascade Biologics, Paisley, UK) were
grown in Medium 200 (Cascade Biologics) supplemented with low
serum growth supplement (Cascade Biologics). Serum-free conditioned
medium was collected as described previously [26,28].
Transfection of PEDF into MatLyLu Rat Prostate Tumor Cells
The human PEDF complementary DNA (cDNA) cloned into
a pCEP4 construct [15] was used for transfection of MatLyLu rat
prostate tumor cells. Cells were transfected with Lipofectamine
(Invitrogen, Stockholm, Sweden) according to the manufacturer’s
instruction. MatLyLu cells transfected with pCEP4 empty plasmid
vector (Invitrogen) were used as controls. Transfected cells were se-
lected using Hygromycin B (Invitrogen). The expression of PEDF
was confirmed by Western blot.
3-(4,5-Dimethylthiazol-2-yl)-2,5 diphenyltetra-zolium
Bromide Viability Assay
Viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyltetra-zoliumbromide (MTT) assay (RocheDiagnostics, Bromma,
Sweden). Briefly, PEDF transfected cells (MatLyLu-PEDF) or control
cells (MatLyLu-CON) (10,000 cells per well) were seeded in 100 μl in
a 96-well plate and incubated in 37°C. After 72 hours, 10 μl of MTT
labeling reagent was added to each well and incubated for an additional
4 hours. Then, 100 μl of solubilization solution was added into each
well and incubated overnight. The following day, absorbance was mea-
sured at 550 nm and subtracted with the reference wavelength at 650 nm.
In Vitro Angiogenesis Assay
For PEDF protein purification, conditioned media from MatLyLu-
PEDF transfected cells was purified on a HisTrapHP column according
to the manufacturer’s instructions (Novagen, Darmstadt, Germany).
The eluted sample was dialyzed against PBS using a dialysis cassette
with 10-kDa cutoff (Pierce Chemical Co, Rockford, IL). Purifica-
tion of PEDF protein was determined by Coomassie-stained SDS-
polyacrylamide gels and Western blot (results not shown).
HUVEC endothelial cell migration was studied in modified Boyden
chambers containing chemotaxis membranes with an 8-μm pore size
(Neuroprobe, Gaithersburg, MD) which were coated with Collagen 1
(Cohesion, Palo Alto, CA). Cells were washed and detached by tryp-
sinization and resuspended in serum-free medium containing 0.1%
BSA. Approximately 10,000 cells were seeded in the top wells. Serum-
free medium with 0.1% BSA containing test substances were placed
in the lower chambers. After incubation for 6 hours at 37°C, filters
were fixed and stained with Giemsa and mounted. Cells attached to
the bottom side of the membrane were counted visually under the mi-
croscope (three high-power fields per well). Six wells per test substance
were assayed, and data were confirmed by two independent experiments.
Serum-free medium containing 0.1% BSA served as a control for back-
ground migration, and fibroblast growth factor 2 (FGF2) (10 ng/ml;
Peprotech, Rocky Hill, NJ) served as a positive control. Purified PEDF
(0.1 μg/ml) alone or in combination with FGF2 was tested. Results
were presented as a percent of the maximal migration toward the posi-
tive control after subtracting the background migration.
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Animal Studies
MatLyLu-PEDF or MatLyLu-CON cells (10,000 cells in 50 μl of
RPMI) were carefully injected into the ventral prostate of Copenhagen
rats as previously described [35]. Animals were killed at 7 (MatLyLu-
PEDF, n = 7; MatLyLu-CON, n = 8) and 23 days (MatLyLu-PEDF,
n = 11; MatLyLu-CON, n = 9) after tumor cell injection. At sacrifice,
the animals were injected with bromodeoxyuridine (BrdU, 50 mg/kg;
Sigma-Aldrich, Oslo, Norway) and anesthetized 1 hour later. The tu-
mor, liver, regional lymph nodes, and lungs were removed, weighed,
fixed in 4% paraformaldehyde, dehydrated, and paraffin-embedded
before morphologic analysis.
AT-1 (2000 cells in 50 μl RPMI, n = 5) were injected into the
ventral prostate of Copenhagen rats as previously described [8]. Ani-
mals were killed at day 10, and tumors were quickly removed, frozen
in liquid nitrogen, and stored at −80°C. Frozen AT-1 tumor tissue was
carefully dissected before protein and RNA extraction. For immuno-
histochemistry staining, the AT-1 tumors were removed, formalin-
fixed, and prepared as earlier described [35].
All the animal work was approved by the local ethical committee
for animal research.
Immunohistochemistry and Morphologic Analyses
Tissue sections were deparaffinized, rehydrated, and washed ac-
cording to standard procedures. Immunohistochemical staining was
performed using primary antibodies against human PEDF (1:100,
cat. MAB1059; Chemicon, Temecula, CA), rat TNFα (1:1000, cat.
AAR33; AbD Serotec, Oxford, UK), synaptophysin (1:100, cat.
A0010; Dako, Stockholm, Sweden), LYVE-1 (1:100, cat. Ab14917;
Abcam, Cambridge, UK), or iNOS (1:500, cat. Ab15323; Abcam)
incubated overnight. After incubating with secondary antibodies, the
slides were then developed using diaminobenzidine (Dako).
Five-micrometer-thick sections were immunostained using pri-
mary antibodies against factor VIII (Dako), BrdU (Dako), caspase-3
(Cell Signaling Technology, Danvers, MA), and CD68 (AbD Serotec)
as described earlier [36–38]. The volume densities (percentages of tis-
sue volume occupied by the defined tissue compartment) of factor
VIII–stained blood vessels, LYVE-1–positive lymph vessels, CD68-
positive macrophages, and iNOS-positive macrophages were assessed
by a point cutting method as earlier described [36,38]. Briefly, a
121-point square lattice mounted in the eyepiece of a light microscope
was used to count the number of intersections falling on the respec-
tive compartment and reference tissue in randomly chosen fields. The
fraction (%) of BrdU-positive proliferating tumor cells and apoptotic
caspase-3–positive tumor cells were measured in approximately 500 cells
in each animal as described earlier [36,38]. Volume density of tumor
tissue at day 7 was determined on hematoxylin-eosin–stained sections
as previously described [35,36,38]. Total tumor weight was then esti-
mated by multiplying the volume density with prostate weight. The size
of lymph node metastasis was estimated by measuring the largest diam-
eter of each metastasis.
TNFα Stimulation In Vitro and In Vivo
AT-1 cells (5 × 105) were seeded in 1 ml of complete medium in a
12-well plate and allowed to settle overnight. The cells were rinsed in
PBS, incubated in serum-free medium for 4 hours, and washed. Rat
recombinant TNFα (Sigma-Aldrich) diluted in serum-free medium
was then added to the cells (1, 10, and 100 ng/ml, three wells per
concentration) and incubated for 18 hours. Serum-free medium was
used as controls (three wells). RNA was then prepared as described
(see below). The results were confirmed in two independent experi-
ments. For protein analysis, AT-1 cells were grown to approximately
70% to 80% confluence and then washed and incubated for 24 hours
with TNFα (100 ng/ml) or control medium (0 ng/ml) in the same
way as for RNA preparation. Serum-free conditioned medium was col-
lected as described previously [26,28]. For in vivo studies, TNFα (1 μg
in 10 μl of PBS, n = 5) or control solution (10 μl of PBS, n = 5) was
injected into the ventral prostate of Copenhagen rats. The animals
were killed after 6 hours, and the ventral prostates were quickly re-
moved and frozen in liquid nitrogen before RNA extraction.
Protein Preparation and Western Blot
Frozen AT-1 tumors were homogenized and transferred into a lysis
buffer as previously described [28]. Protein extracts were then pooled
together (n = 3). The BCA Protein Assay (Pierce) was used to deter-
mine the protein concentration.
Western blot was performed as previously described [28] using pri-
mary antibodies for PEDF ([15] for rat PEDF and Chemicon for hu-
man PEDF, at 1:1000, for 1 hour). Molecular-size standards (BioRad
Laboratories AB, Hercules, CA) were included as controls.
RNA Preparation, RT 2 Profiler PCR Arrays, and Real-time
Quantitative Reverse Transcription–Polymerase
Chain Reaction
RNA, from ventral prostate, AT-1 tumors (n = 5), AT-1 cells (n =
3 different cell batches), and MatLyLu-transfected cells, was ex-
tracted using the TRIzol method (Invitrogen) following the manu-
facturer’s instructions.
For polymerase chain reaction (PCR) array studies, MatLyLu-PEDF
cells (n = 4 different cell batches, pooled into one sample) were com-
pared with MatLyLu-CON cells (n = 4 different cell batches, pooled
into one sample). Total RNA was DNase-treated, and complement-
ary DNA (cDNA) was synthesized on 1 μg as previously described
[8]. RT2 Profiler PCR arrays, rat angiogenesis (cat. APRN-024A;
SABiosciences, Frederick, MD), and rat chemokines (cat. PARN-022A;
SABiosciences) were performed and analyzed as previously described
[8] and according to the manufacturer.
Quantification of PEDF mRNA levels was performed by real-time
quantitative reverse transcription–PCR using the LightCycler SYBR
Green I technology (Roche Diagnostics) as previously described and
according to a protocol [28]. Melting curve analysis was performed to
confirm specificity. Negative controls were run in parallel. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA was analyzed to con-
trol that equal levels of RNA were analyzed [28]. Data were analyzed
using LightCycler Analysis Software 3.5.3 (Roche Diagnostics).
Statistical Analysis
Values are presented as mean ± SD. The Mann-Whitney U test
was used for comparison between groups. P < .05 was considered
significant. Statistical analysis was performed using the statistical soft-
ware SPSS 16.0 (SPSS, Inc., Chicago, IL).
Results
PEDF-Transfected Rat Tumor Cells Secreted Biologically
Active PEDF
To study the effects of PEDF on prostate tumor growth and me-
tastasis, we transfected rat MatLyLu prostate tumor cells, a metastatic
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cell type that normally lacks PEDF expression [28], with a plasmid
vector containing human PEDF cDNA (MatLyLu-PEDF). Control
cells were transfected with the same vector lacking PEDF cDNA
(MatLyLu-CON). PEDF was detected in conditioned medium of
MatLyLu-PEDF cells, whereas the conditioned medium of control
cells was negative (Figure 1A). Purified PEDF protein from MatLyLu-
PEDF conditioned medium inhibited HUVEC migration above the
basal levels (Figure 1B) in line with effects reported earlier for recom-
binant PEDF [15]. These results show that the PEDF protein was
synthesized, secreted, and biologically active. However, viability did
not differ between PEDF-transfected and control cells, indicating that
PEDF overexpression did not have strong effects on the MatLyLu cells
in vitro (Figure 1C).
PEDF Overexpression Slowed Orthotopic Prostate Tumor
Growth, Inhibited Angiogenesis, and Repressed the Growth
of Lymph Node Metastasis
To evaluate the growth rate of MatLyLu-PEDF cells in vivo, a
small number of cells (1 × 104) were injected into the ventral prostate
of Copenhagen rats and compared with controls at 7 and 23 days
after injection.
Tumor size was significantly smaller in the MatLyLu-PEDF tumors
compared with controls at both time points (Table 1). However, tumor
growth between days 7 and 23 was high in both MatLyLu-PEDF tu-
mors and controls and was probably due to transient PEDF expression
in vivo. At day 7, human PEDF mRNA (data not shown) and protein
was expressed in MatLyLu-PEDF tumors, whereas MatLyLu-CON tu-
mors were negative. Immunohistochemistry at day 7 showed that some
tumor cells where highly immunoreactive for PEDF, whereas others
were completely unstained, and at 23 days, the protein expression
was no longer detected (Figure 1D). The transient expression of PEDF
expression was probably due to loss of the expression plasmid during
tumor expansion, and we, therefore, further analyzed the tumors at
day 7 when PEDF protein was present.
Histologic analysis at day 7 showed that PEDF inhibited angio-
genesis in the MatLyLu-tumors and in the nearby normal prostate
tissue (Table 1). Surprisingly, MatLyLu-PEDF tumors contained more
lymphatic vessel in the tumor adjacent prostate tissue compared with
controls (Table 1). Further, PEDF did not affect tumor cell prolifera-
tion, and although tumor cell apoptosis was increased, it did not reach
statistical significance, indicating that tumor growth was inhibited dur-
ing earlier time points. Previous studies have shown that PEDF could
suppress prostate tumor growth by inducing neuroendocrine differ-
entiation [27]. We could, however, not detect any neuroendocrine
marker expression (synaptophysin) or phenotype in MatLyLu-PEDF
tumors (data not shown).
Examination of abdominal lymph node and lung tissue showed no
signs of metastasis at the earlier time point. At day 23, abdominal
Figure 1. (A) Western blot analysis of PEDF in PEDF-transfected
(MatLyLu-PEDF) and vector-transfected MatLyLu (MatLyLu-CON)
cells in vitro. (B) PEDF purified from MatLyLu-PEDF medium was
tested for its ability to inhibit migration of HUVECs toward angio-
genic FGF2. Results are presented as percentage maximum migra-
tion induced by the positive control (FGF2) after the background
migration of endothelial cells was subtracted. (C) Cell viability was
measured in MatLyLu-PEDF and control cells after 72 hours using
an MTT assay. (D) Sections from orthotopic MatLyLu-PEDF and
MatLyLu-CON tumors immunostained with an antibody against hu-
man PEDF (Chemicon).
Table 1. Histologic Analysis of MatLyLu-PEDF and Control Tumors.
MatLyLu-CON MatLyLu-PEDF P
MatLyLu-PEDF (n = 8) and control tumors (n = 7 ) at day 7
Tumor weight (g) 0.045 (0.024) 0.015 (0.013) .02
Vascular density (intratumoral)
factor VIII (%)
4.7 (0.7) 2.6 (1.2) .008
Vascular density (extratumoral)
factor VIII (%)
4.3 (1.0) 2.6 (0.9) .005
Lymphatic vessel density (extratumoral)
LYVE-1 (%)
0.5 (0.1) 0.8 (0.2) .009
Apoptosis caspase-3 (%) 1.2 (0.5) 1.8 (0.6) .08
Proliferation BrdU (%) 26.3 (3.4) 22.0 (6.5) .2
MatLyLu-PEDF (n = 11) and control tumors (n = 9) at day 23
Tumor weight (g) 28 (9.0) 19 (7.4) .04
Lymph node metastasis (mm) 3.7 (2.0) 1.1 (1.0) .005
Values are means (SD).
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lymph node metastases were seen in all nine control animals, and in
addition, metastases to lungs and/or liver were detected in three of
nine MatLyLu-CON animals. In the MatLyLu-PEDF group, lymph
node metastases were seen in 8 of 11 examined animals, but the aver-
age diameter of the metastases was significantly reduced compared
with controls (Table 1). Metastases to the lung and/or liver were only
seen in 1 of the 11 PEDF transfected animals. Transient overexpres-
sion of PEDF was thus sufficient to temporarily inhibit growth of
prostate tumors and their metastases.
PEDF Transfection Influenced the Expression of Vascular
Regulators and Cytokines in Prostate Cancer Cells
To better understand the mechanisms behind PEDF’s antiangio-
genic effects and to study if PEDF induced chemokine’s expressions,
MatLyLu-PEDF cells were compared with control cells using a rat
chemokine and a rat angiogenesis PCR array. The results showed that
PEDF expression induced MatLyLu cells in vitro to express other anti-
angiogenic factors such as bone morphogenetic protein 6 (Bmp6) [39],
tissue inhibitor of metalloproteinase 2 [40], midkine [41], and the
metastasis suppressor maspin [42] (Table 2). However, proangiogenic
factors, for example, FGF2, matrix metalloproteinase 9 (MMP9), pla-
cental growth factor (PlGF), and ephrin A1, were also increased [43]
(Table 2). As the tumor in vivo showed decreased angiogenesis, these
observations emphasize the importance of the net balance of proangio-
genic and antiangiogenic molecules.
MatLyLu-PEDF tumor cells also had increased expression of several
chemokines in vitro compared with MatLyLu-CON cells (Table 2).
A subset of these has been shown to stimulate infiltration of macro-
phages in other tissues, for example, chemokines ligand 6 (CCL6) [44]
and PlGF [45]. The recruitment factors MCP-1/CCL2 and colony-
stimulating factor 1 were, however, not increased in the MatLyLu-
PEDF tumor cells compared with controls.
PEDF Overexpression Increased Tumor Macrophage
Recruitment In Vivo
To examine if PEDF overexpression could influence monocyte/
macrophage infiltration, we stained the tumors for CD68 (Figure 2A).
Surprisingly, MatLyLu-PEDF tumors and their surrounding prostate
tissue contained significantly more macrophages than MatLyLu-CON
tumors (Figure 2B).
TAMs are present in most established tumors and differentiate
into cytotoxic (M1) macrophages but more generally to the tumor
growth-promoting (M2) state [4]. Increased iNOS is a characteristic
of M1 macrophages [46]. To compare iNOS expression in vivo, we
stained MatLyLu-PEDF tumors and controls using an iNOS anti-
body (Figure 2A). The volume density of iNOS-positive macrophages
increased in the MatLyLu-PEDF tumors compared with controls
both in the nonmalignant tissue and in the tumor (Figure 2C ). More
than half of the TAMs in the extratumoral nonmalignant tissue were
iNOS-positive in both MatLyLu-PEDF tumors and controls (Fig-
ure 2D). Inside the tumor, the fraction of iNOS-positive macrophages
was lower compared with the extratumoral tissue, suggesting a shift
in the macrophage phenotype in the tumor microenvironment.
Furthermore, the data show that, although iNOS-positive macro-
phages are a minor fraction of the TAMs inside the MatLyLu tumors,
their proportion increased when the tumors overexpressed PEDF
(Figure 2D).
PEDF Levels in Prostate Tumors Were Suppressed by the
Microenvironment and TNFα
Because prostate tumors and tumor cell lines often, and for reasons
unknown, lack PEDF expression [26,28], it was of interest to explore
how PEDF was regulated in the prostate and in prostate tumors.
To start exploring this, we first examined how prostate tumor cells
normally expressing PEDF behave when placed in a prostate micro-
environment. AT-1 tumor cells that express high levels of PEDF mRNA
and protein in vitro and as subcutaneous tumors [28] were injected
into the ventral prostate of Copenhagen rats. Interestingly, PEDF
mRNA and protein levels were downregulated in AT-1 tumors grow-
ing in the prostate compared with the tumor cells in vitro (Figure 3, A
and B), suggesting that some factor in the prostate microenvironment
suppressed the PEDF intratumoral system. To ensure that equal levels
of RNA were analyzed, GAPDH mRNA levels were quantified. No
significant difference in the GAPDH mRNA levels was observed (data
not shown).
In previous studies, we have shown that intraprostatic injection
of AT-1 cells results in the accumulation of inflammatory cells such
Table 2. Chemokines and Angiogenic Factors Altered in MatLyLu-PEDF Cells Compared with
MatLyLu-CON Cells In Vitro (Two-fold Cutoff ).
Accession No. Symbol Description Fold Change
in Superarray
Angiogenic factors
NM_031530 CCL2/MCP-1 Chemokine (C-C) ligand 2 −3.30
XM_343607 Col4a3 Collagen, type IV, α 3 −2.24
NM_145672 CXCL9/Mig Chemokine (C-X-C) ligand 9 −3.37
NM_053599 Efna1 Ephrin A1 2.77
NM_001010968 Eng Endoglin 3.44
NM_022924 F2 Coagulation factor 2 2.79
NM_019305 Fg f-2/bFGF Fibroblast growth factor 2 2.22
NM_131908 Fg f-6 Fibroblast growth factor 6 2.11
NM_019143 Fn-1 Fibronectin 1 2.27
NM_024359 Hif1α Hypoxia-inducible factor 1 α 2.91
NM_012589 IL6 Interleukin 6 2.92
XM_215963 Lama5 Laminin, α 5 3.41
NM_030854 Lect1 Leukocyte cell derived chemotaxin 1 −2.38
NM_030859 Mdk Midkine 6.19
NM_031055 Mmp9 Matrix metalloproteinase 9 7.82
U77697 Pecam Platelet/endothelial cell adhesion molecule 2.60
NM_053595 Plg f Placental growth factor 2.03
NM_057108 Serpinb5 Maspin 2.73
NM_012671 TGFα Transforming growth factor α 3.00
NM_021578 TGFβ2 Transforming growth factor β 2 2.54
NM_013174 TGFβ3 Transforming growth factor β 3 2.08
NM_053819 Timp-2 Tissue inhibitor of metalloproteinase 2 2.72
Chemokines
NM_011349 Agtrl1 Angiotensin receptor-like 1 2.93
NM_013107 Bmp6 Bone morphogenetic protein 6 2.93
NM_016994 C3 Complement component 3 3.96
NM_078621 Ccbp2 Chemokine binding protein 2 2.15
NM_057151 Ccl17 Chemokine (C-C motif ) ligand 17 3.84
NM_0010042 Ccl6 Chemokine (C-C motif ) ligand 6 17.17
NM_0010123 Ccl9 Chemokine (C-C motif ) ligand 9 3.38
NM_020542 Ccr1 Chemokine (C-C motif )receptor 1 −9.18
NM_133532 Ccr4 Chemokine (C-C motif ) receptor 4 2.15
NM_0010131 Ccr6 Chemokine (C-C motif ) receptor 6 2.22
NM_172329 Ccr9 Chemokine (C-C motif )receptor 9 5.48
NM_022218 Cmklr1 Chemokine-like receptor 1 5.30
NM_053352 Cmkor1 Chemokine orphan receptor 1 5.98
NM_182952 Cxc111 Chemokine (C-X-C motif ) ligand 11 4.14
NM_053647 Cxcl2 Chemokine (C-X-C motif ) ligand 2 3.96
NM_017001 Epo Erythropoietin 5.28
XM_344130 Inhbb Inhibin β-B 5.66
NM_022196 Lif Leukemia inhibitory factor 2.17
NM_019340 Rgs3 Regulator of G protein signaling 3 2.08
NM_019178 Tlr4 Toll-like receptor 4 24.93
340 PEDF in Prostate Cancer Halin et al. Neoplasia Vol. 12, No. 4, 2010
as macrophages and mast cells in the tumor and in the surrounding
normal tissue [8] (Johansson et al., unpublished data). It is there-
fore possible that factors secreted by inflammatory cells downregu-
late endogenous PEDF expression possibly as a negative feedback
loop. Immunohistochemical staining showed that inflammatory cells,
mainly macrophages, were positively stained for TNFα, whereas
AT-1 tumor cells were negative (Figure 3C ). TNFα stimulation of
AT-1 cells in vitro significantly decreased PEDF mRNA levels in a
dose-dependent manner (Figure 3D). GAPDH mRNA levels were
unaffected, and TNFα did not affect cell viability after the 18-hour
incubation (data not shown). In addition, TNFα decreased PEDF
protein in conditioned medium of AT-1 cells (Figure 3E ). To test
if TNFα could regulate the expression of PEDF in vivo, a single
dose of TNFα (1 μg per animal) was injected into the ventral pros-
tate of Copenhagen rats, and the animals were killed 6 hours later.
The results showed that TNFα significantly downregulated PEDF
mRNA also in normal rat prostate tissue in vivo (Figure 3F ). GAPDH
mRNA expression did not differ significantly between the groups (data
not shown).
Discussion
MatLyLu rat prostate tumors are highly aggressive and metastatic and
express low levels of PEDF in vivo and in vitro [28]. Here, we tran-
siently transfected MatLyLu tumor cells with a plasmid vector express-
ing human PEDF. Consistent with studies in other cancer types [16–
22], PEDF overexpression also repressed orthotopic MatLyLu tumor
growth, delayed the growth of metastasis, and suppressed angiogenesis
both in the tumor and in the surrounding normal prostate. The anti-
angiogenic effects seen in this model could be due to direct inhibitory
effects of PEDF on blood vessels or indirect effects caused by other fac-
tors upregulated by PEDF. For example, angiogenesis inhibitors such
as maspin [42], midkine [41], and Bmp6 [39] were upregulated, but
stimulators such as MMP9, FGF2, and PlGF were also upregulated.
Exploiting the antiangiogenic effects of PEDF could thus be a novel
way to treat prostate cancer, but our findings suggest that PEDF also
has additional functions.
Interestingly, we also found that PEDF-transfected tumors contained
more macrophages both in the tumor and in the adjacent prostate tissue
than controls. Whether increased macrophage recruitment inhibits
Figure 2. (A) Sections from MatLyLu-PEDF tumors and controls at day 7 showing consecutive areas stained for CD68 and iNOS-positive
macrophages. (B) Volume densities (%) of CD68-positive macrophages and (C) iNOS-positive macrophages in the nonmalignant extra-
tumoral tissue and intratumorally in MatLyLu-PEDF tumors and controls at day 7. (D) Percentage of iNOS-positive macrophages (iNOS/
CD68) in the extratumoral and intratumoral tissues of MatLyLu-PEDF tumors and controls at day 7. Values are expressed as means ±
SD. *P < .05, **P < .01.
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or enhances tumor growth depends on their differentiation state,
cytotoxic M1 macrophages inhibit tumor growth, whereas M2 macro-
phages are tumor promoting [3,4]. The tumor microenvironment
generally directs macrophages toward the tumor-promoting phenotype,
and we have previously shown that an overall reduction of monocyte/
macrophage recruitment to rat AT-1 prostate tumors represses tumor
growth and angiogenesis [8]. Here, we could demonstrate that the
proportion of iNOS-positive macrophages (most likely M1) decreased
inside the orthotopic MatLyLu tumor compared with the extratumoral
nonmalignant prostate tissue, suggesting a shift in macrophage differ-
entiation in the tumor microenvironment. Although iNOS-positive
macrophages constituted a minor fraction of the total macrophage den-
sity in the MatLyLu tumors, the proportion was increased when the
tumors overexpressed PEDF. This suggests that PEDF, in addition to
its antiangiogenic functions, could also enhance antitumor immunity
by increasing M1 macrophage numbers. Increased macrophage infiltra-
tion coupled with a shift fromM2 toM1macrophages by GM–colony-
stimulating factor treatment has been shown to suppress breast cancer
growth, angiogenesis, and metastasis [47]. Interestingly, another potent
angiogenesis inhibitor, thrombospondin 1, has also been shown to pro-
mote M1 tumor macrophage recruitment and cytotoxicity [48].
The reason for the increased macrophage content is unknown, but
PEDF has, in other tissues, been shown to either stimulate or repress
the expression of several chemokines such as MCP-1/CCL2, macro-
phage inflammatory protein 1α, 2, and 3α, interleukin 1β, interleu-
kin 6, and TNFα [9,10,13,49]. In this study, PEDF stimulated the
expression of several chemokines and other factors in the MatLyLu
tumor cells in vitro, which could directly or indirectly, through other
Figure 3. (A) Western blot analysis of PEDF in conditioned medium of AT-1 cells in vitro and in tumor lysates from orthotopic AT-1
tumors at day 10. (B) Relative PEDF mRNA levels in AT-1 cells in vitro (n = 3 different batches) and in orthotopic AT-1 tumors in vivo
at day 10 (n = 5). (C) Sections from an AT-1 tumor at day 10 showing consecutive areas stained for macrophages (CD68) and TNFα. (D)
Relative PEDF mRNA expression in AT-1 cells stimulated with indicated concentrations of TNFα for 18 hours in vitro. (E) Western blot
analysis of PEDF in conditioned medium of AT-1 cells stimulated with indicated concentrations of TNFα for 24 hours. (F) Relative PEDF
mRNA levels quantified from ventral prostate of Copenhagen rats injected with control (PBS, n = 5) or recombinant rat TNFα (1 μg, n =
5). Values are means ± SD. *P < .05, **P < .01.
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immune cells, result in macrophage recruitment [45,50]. CCL6,
which attracts macrophages in rodents [44], was particularly upreg-
ulated, suggesting that it could be involved. Interestingly, Toll-like
receptor 4 (TLR4) mRNA expression was highly increased in MatLyLu-
PEDF cells compared with controls, and down-regulation of TLR4
signaling makes prostate cancer cells less aggressive [51]. Activation
of TLR4 induces expression of several chemokines [52,53]. PEDF
could therefore indirectly stimulate monocyte recruitment and make
tumor cells more malignant by upregulating TLR4.
The possibility that increased macrophage accumulation to the
MatLyLu-PEDF tumors also could be stimulatory is supported by
the increase in lymphangiogenesis seen in the extratumoral prostate
tissue. Lymphatic endothelial migration and survival is mainly stim-
ulated by activation of vascular endothelial growth factor receptor 3
(VEGF-R3) by VEGF-C and D [54]. PEDF has been shown to
stimulate both VEGF-C and VEGF-R3 expressions in endothelial
HUVECs under hypoxia [55]. Here, in normoxic conditions in vitro,
no difference in MatLyLu VEGF-C or VEGF-D mRNA levels could
be detected. Because MatLyLu tumors are hypoxic in vivo (unpub-
lished data), PEDF could possibly stimulate VEGF-C expression in
this context. Macrophages are, however, by secreting VEGF-C and
VEGF-D, potent stimulators of peritumoral lymphangiogenesis [56].
Therefore, PEDF could, indirectly by stimulating macrophage infil-
tration to the tumors, stimulate lymphangiogenesis. Because lymph-
angiogenesis could enhance the metastatic potential of tumors [57],
these findings are contradictory to PEDF as a clean metastasis suppres-
sor and therefore warrant further investigations.
PEDF expression is often decreased or lost in prostate tumors and
prostate tumor cell lines [26,28]. The reason for this is unknown, but
hypoxia and androgens can downregulate PEDF protein in prostate
stromal and tumor cells [26]. In our previous work, we could find sub-
sets of aggressive human prostate tumors that still contained PEDF;
however, immunohistochemistry showed that the expression of PEDF
was heterogeneous [28]. Orgaz et al. [33] showed that a single mela-
noma lesion may contain both PEDF-positive and -negative cells and
that PEDF expression was restricted to the less aggressive tumor cells.
Regulatory signals from the microenvironment may provide a mecha-
nism underlying such changes in PEDF expression. This was sup-
ported by our results showing that injection of AT-1 tumor cells
into the prostate of Copenhagen rats markedly decreased the expres-
sion of endogenous PEDF compared with the levels in vitro. AT-1 tu-
mor cells placed subcutaneously, however, did not decrease PEDF
expression [28] (unpublished data), suggesting that some factor in the
prostate microenvironment inhibited PEDF expression. Our AT-1 tu-
mors are hypoxic [35], and hypoxia is therefore one likely explanation
for the decreased levels of PEDF in the orthotopic tumors compared
with the tumor cells in vitro. Hypoxia-induced down-regulation has,
however, only been seen at the translational/posttranslation level and
not at the transcriptional level [15], but in the AT-1 tumors, both
mRNA and protein were markedly reduced. Furthermore, androgens
should not affect the AT-1 tumors because they lack the androgen re-
ceptor [35,58]. This prompted us to look for additional regulatory
mechanisms for PEDF. Macrophages and other inflammatory cells such
as T cells and mast cells accumulate in the AT-1 tumors and in the
surrounding normal tissue [8] (Johansson et al., unpublished data).
We could show that these inflammatory cells, mainly macrophages
but also other inflammatory cells, express TNFα and that TNFα
downregulated PEDF expression in AT-1 cells in vitro and in the ven-
tral prostate in vivo. These results suggest that tumor infiltration by
TNFα-expressing macrophages could eventually facilitate angiogenesis,
tumor growth, and metastasis by repressing PEDF expression in pros-
tate tumor cells. As PEDF overexpression stimulated increased macro-
phage infiltration toMatLyLu tumors, it is possible that TNFα secreted
by macrophages could work as a negative feedback loop for PEDF
expression. Loss of PEDF overexpression in the MatLyLu tumors is,
however, probably due to loss of the expression plasmid during tumor
growth. TNFα has also been shown to decrease PEDF mRNA in
HUVECs [59]. Interestingly, accumulating immune cells secreting
RANK-ligand affecting NFκB signaling in prostate tumor cells have
also been shown to inhibit the secretion of another metastasis inhibit-
ing serpin maspin [60], which was upregulated in vitro by PEDF over-
expression in our study. Infiltrating macrophages may thus enhance
prostate tumor progression by downregulating endogenous antiangio-
genic and metastasis-suppressing factors.
PEDF is a potent tumor suppressor and is therefore a promising
anticancer therapy. Here, we also show that PEDF, besides inhibiting
angiogenesis, also increased the fraction of iNOS-positive and most
likely cytotoxic macrophages to prostate tumors, suggesting an addi-
tional antitumor function. Accumulating macrophages may, however,
by secreting TNFα and other factors, suppress the secretion of PEDF
and other inhibitors of angiogenesis and promote lymphangiogenesis
and, in this way, facilitate tumor progression. PEDF treatment could
therefore be a double-edged sword, and to clarify its potential use in
treatment, the multiple functions of this protein need to be thor-
oughly investigated.
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